Bronchiectasis
-
Final Pediatric Core Curriculum Session Features Systemic Disease Considerations and Novel Testing in Bronchiectasis
on
Read more: Final Pediatric Core Curriculum Session Features Systemic Disease Considerations and Novel Testing in BronchiectasisThe Pediatric Clinical Core Curriculum will host its third and final session at 9:30 a.m. on Wednesday. Carmen Leon Astudillo, MD, explained that the series will provide pulmonologists with guidance for treating patients with potential immunological or rheumatologic disorders that can lead to bronchiectasis.
-
Pediatric Clinical Core Curriculum Dives Deep into Bronchiectasis
on
Read more: Pediatric Clinical Core Curriculum Dives Deep into BronchiectasisThe Pediatric Clinical Core Curriculum at the ATS 2026 International Conference kicks off its three-part series with sessions from noon–1 p.m. on Sunday and Monday. Series Chair Moshe Prero, MD, shared that this year’s curriculum will review current and emerging trends in the diagnosis and management of pediatric patients with bronchiectasis.
-
Explore the Latest Developments in Bronchiectasis During ATS 2026 Orlando
on
Read more: Explore the Latest Developments in Bronchiectasis During ATS 2026 OrlandoIn August 2025, clinicians and researchers who treat patients with bronchiectasis reached a significant milestone with the FDA approval of brensocatib, the first treatment developed for non-cystic fibrosis bronchiectasis in adults and pediatric patients aged 12 and older. In an interview with ATS Conference News, Dan Belz, MD, MPH, explained the significance of this milestone…
-
Bronchiectasis and COPD Lineup at ATS 2026 Orlando
on
Read more: Bronchiectasis and COPD Lineup at ATS 2026 OrlandoATS 2026 Orlando offers a robust scientific program, featuring a variety of scientific symposia, abstract presentations, and Meet the Expert sessions to examine the latest investigative insights and clinical challenges for treating bronchiectasis and COPD.